OncBioMune reports additional Phase I data for prostate cancer vaccine

OncBioMune Pharmaceuticals Inc. (OTCQB:OBMP) reported additional data from 14 evaluable patients with hormone-naïve and hormone-independent recurrent prostate cancer with increasing prostate-specific antigen (PSA; KLK3) levels in a Phase I trial showing that six intradermal injections of ProscaVax led to a one-year progression-free survival (PFS) rate of 71.4% and a one-year overall survival (OS) rate of 100%. The trial is being conducted in collaboration with the U.S. Department of Defense. The company previously reported data from the trial (see BioCentury, March 7, 2016).

The open-label, U.S. trial's primary endpoint is DLTs. Secondary endpoints include PSA doubling time and prostate acid phosphate (PAP) levels, time to measurable disease, time to subsequent therapy, OS and vaccine-induced immune response...